Last reviewed · How we verify
Subutex, Buprenorphine Hydrochloride, SCH 28444
Subutex, Buprenorphine Hydrochloride, SCH 28444 is a Partial mu-opioid receptor agonist Small molecule drug developed by Indivior Inc.. It is currently FDA-approved for Opioid use disorder (maintenance treatment and detoxification), Pain management (off-label use in some jurisdictions).
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder. Used for Opioid use disorder (maintenance treatment and detoxification), Pain management (off-label use in some jurisdictions).
At a glance
| Generic name | Subutex, Buprenorphine Hydrochloride, SCH 28444 |
|---|---|
| Sponsor | Indivior Inc. |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system but produces only partial agonist activity, meaning it produces a ceiling effect that limits euphoria and overdose risk compared to full opioid agonists. This partial agonism simultaneously suppresses withdrawal symptoms and reduces the reinforcing effects of illicit opioids, making it effective for opioid maintenance therapy and addiction treatment.
Approved indications
- Opioid use disorder (maintenance treatment and detoxification)
- Pain management (off-label use in some jurisdictions)
Common side effects
- Headache
- Constipation
- Nausea
- Insomnia
- Sweating
- Dizziness
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subutex, Buprenorphine Hydrochloride, SCH 28444 CI brief — competitive landscape report
- Subutex, Buprenorphine Hydrochloride, SCH 28444 updates RSS · CI watch RSS
- Indivior Inc. portfolio CI
Frequently asked questions about Subutex, Buprenorphine Hydrochloride, SCH 28444
What is Subutex, Buprenorphine Hydrochloride, SCH 28444?
How does Subutex, Buprenorphine Hydrochloride, SCH 28444 work?
What is Subutex, Buprenorphine Hydrochloride, SCH 28444 used for?
Who makes Subutex, Buprenorphine Hydrochloride, SCH 28444?
What drug class is Subutex, Buprenorphine Hydrochloride, SCH 28444 in?
What development phase is Subutex, Buprenorphine Hydrochloride, SCH 28444 in?
What are the side effects of Subutex, Buprenorphine Hydrochloride, SCH 28444?
What does Subutex, Buprenorphine Hydrochloride, SCH 28444 target?
Related
- Drug class: All Partial mu-opioid receptor agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Indivior Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry / Addiction Medicine
- Indication: Drugs for Opioid use disorder (maintenance treatment and detoxification)
- Indication: Drugs for Pain management (off-label use in some jurisdictions)
- Compare: Subutex, Buprenorphine Hydrochloride, SCH 28444 vs similar drugs
- Pricing: Subutex, Buprenorphine Hydrochloride, SCH 28444 cost, discount & access